IRONWOOD PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on the 31 st day of March 2025.
| | ||
|---|---|---|
| | Ironwood Pharmaceuticals, Inc. | |
| | By: | /s/ Thomas McCourt |
| | | Thomas McCourt |
| | | Chief Executive Officer |
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.
| Signature | Title | Date | ||
|---|---|---|---|---|
| | | | | |
| /s/ Thomas McCourt | | Chief Executive Officer and Director (Principal Executive Officer) | | March 31, 2025 |
| Thomas McCourt | | | ||
| /s/ Gregory Martini | | Senior Vice President, Chief Financial Officer (Principal Financial Officer) | | March 31, 2025 |
| Gregory Martini | ||||
| /s/ Ronald Silver | | Senior Vice President, Corporate Controller (Principal Accounting Officer) | | March 31, 2025 |
| Ronald Silver | | | ||
| | | | | |
| /s/ Julie H. McHugh | | Chair of the Board | | March 31, 2025 |
| Julie H. McHugh | | | ||
| | | | | |
| /s/ Mark Currie | | Director | | March 31, 2025 |
| Mark Currie | | | ||
| | | | | |
| | | Director | | |
| Alexander Denner | | | ||
| | | | | |
| /s/ Andrew Dreyfus | | Director | | March 31, 2025 |
| Andrew Dreyfus | | | ||
| | | | | |
| /s/ Jon Duane | | Director | | March 31, 2025 |
| Jon Duane | | | ||
| | | | | |
| /s/ Marla Kessler | | Director | | March 31, 2025 |
| Marla Kessler | | | ||
| | | | | |
| /s/ Catherine Moukheibir | | Director | | March 31, 2025 |
| Catherine Moukheibir | | | ||
| | | | | |
| /s/ Jay P. Shepard | | Director | | March 31, 2025 |
| Jay P. Shepard | | | ||
| | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.